Shares of Genus plc climbed 3.2% after the British animal genetics firm published an updated fiscal 2026 earnings outlook. The company now expects adjusted profit before tax for fiscal 2026 of approximately A398 million, modestly ahead of the market consensus of A395.5 million.
Genus said trading in the second half exceeded its prior expectations. Within its PIC business, growth across Asia - including China - and Latin America was strong, which more than offset a weaker performance in North America that the company attributed to customer disease challenges.
The ABS division delivered double-digit profit growth, the company added, with continued tailwinds from its Value Acceleration Programme helping to offset softer customer demand and an adverse product mix that management linked to lower global dairy prices.
Genus highlighted very strong cash conversion in the second half, which it said translated into significant growth in expected free cash flow generation for fiscal 2026. In the fourth quarter the company received approximately A3111 million of net cash consideration from Beijing Capital Agribusiness after completing the formation of a Chinese porcine joint venture earlier in the year.
As a result of the improved cash position, Genus said year-end net leverage will be significantly reduced to approximately 0.4x. The fiscal 2026 adjusted profit before tax guidance includes a final A35.6 million milestone payment received earlier in the year from the company's Chinese partner, Beijing Capital Agribusiness.
Genus is scheduled to publish its fiscal 2026 preliminary results on September 10, 2026.
Key points
- Updated fiscal 2026 adjusted profit before tax guidance of approximately A398 million versus market consensus of A395.5 million.
- PIC division strength in Asia, including China, and Latin America offset weaker North American performance caused by customer disease issues; ABS posted double-digit profit growth aided by the Value Acceleration Programme.
- Very strong second-half cash conversion and a A3111 million net cash receipt from Beijing Capital Agribusiness materially improve free cash flow and reduce year-end net leverage to about 0.4x.
Risks and uncertainties
- Customer disease challenges in North America that weighed on PIC performance represent an operational risk that could continue to affect regional results.
- Softer customer demand and an adverse product mix driven by lower global dairy prices have pressured ABS margins, creating market-demand and pricing-related uncertainty.
- The company's guidance and balance sheet improvement reflect one-off cash consideration and milestone payments from the Chinese partner; future guidance may be affected by timing or size of such receipts and by the upcoming fiscal 2026 preliminary results due September 10, 2026.
Genus' updated guidance and the associated cash receipts underpin the immediate market reaction, but the company continues to flag regional operational variability and product-mix impacts that investors and sector analysts will monitor. The numbers disclosed - guidance of roughly A398 million in adjusted pre-tax profit, the A3111 million JV-related net cash inflow and the A35.6 million milestone payment included in guidance - are central to the company's near-term financial profile ahead of its formal results announcement in September.